http://www.biomedreports.com/2012010...s-disease.html

sure would be nice but how are lung cells affected.

no carbidopa?

About CVT-301

Civitas’ lead program, CVT-301, is an inhaled formulation of L-dopa for the immediate relief from debilitating motor fluctuations associated with Parkinson’s disease. For symptomatic relief, oral L-dopa is administered to maintain dopamine levels in the brain above the therapeutic threshold; yet the efficacy of oral L-dopa is significantly compromised by delayed absorption and excessive variability in the circulating plasma drug concentrations inherent to the oral delivery route. CVT-301 is an ARCUS(TM) therapeutic that incorporates L-dopa and is optimized to deliver a precise dose to the deep lung for rapid and predictable L-dopa absorption. The ARCUS(TM) platform is uniquely able to deliver the necessary L-dopa dose with the required precision. CVT-301 is being developed as an adjunct to standard oral L-dopa therapy to enable patients to manage motor fluctuations caused in part by the inter-dose variability of oral L-dopa. In preclinical models, CVT-301 has demonstrated immediate and consistent increases in L-dopa peak plasma concentration providing rapid, durable symptomatic relief, even when compared to larger doses of oral L-dopa.
http://www.biomedreports.com/2012010...s-disease.html

This raises hope! It would be great if they live up to their claim that they can control the dose of l-dopa needed by the brain through inhaling the l-dopa powder, and I agree that safety must be a serious concern.
Eliminating Carbidopa from the formula, IMHO, is a big bonus.
I must also mention that Ronhutton has suggested this idea repeatedly on this forum years back !
Thank you Soccertease for sharing.